Loading…
Loading…
Aclarion (NASDAQ: ACON - Get Free Report) and Todos Med (OTCMKTS:TOMDF - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Institutional and Insider Ownership 7.5% of Aclarion shares are
Auna (NYSE: AUNA - Get Free Report) and Todos Med (OTCMKTS:TOMDF - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations. Risk and Volatility Auna has a beta of 2.09,
Todos Med (OTCMKTS:TOMDF - Get Free Report) and GeneDx (NASDAQ: WGS - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends. Valuation and Earnings This table compares Todos Med and
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, Israel, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), an innovative healthcare solutions company, today announced that a trustee was appointed (the “Trustee”) with respect to an insolvency order that was issued with respect to the Company in Israel related to a request for liquidation filed by the Company's Founder and former Director, President & CEO Rami Zigdon.
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Todos Medical, Ltd. (OTCQB: TOMDF), an innovative healthcare solutions company, today provided a corporate update to its stakeholders centered on the Company's efforts to retool and focus primarily on addressing the Long COVID epidemic that is affecting over 15 million Americans, over 6% of the adult US population, according to the US Centers for Disease Control. Todos intends to deploy medical foods to aid physicians in the dietary management of Long COVID, optimize immune support with nutritional supplements targeting the 3CL protease, and precision diagnostic panels to assist in the diagnosis and monitoring of Long COVID patients. A recent report by David Cutler of Harvard University estimates the annual Long COVID cost to the US economy is $3.7 trillion.
Claims covering inhibition of 3CL protease, inflammation and autophagy underscore Dr. Dorit Arad's lifelong work NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, Aug. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Todos Medical, Ltd. (OTCQB: TOMDF), a medical diagnostics and related solutions company, today announced that the United States Patent & Trademark Office (USPTO) has issued a Notice of Allowance for NLC Pharma's patent application entitled "Compounds for Treating a Coronavirus Infection” prosecuted from the groundbreaking work of Dr. Dorit Arad.
Todos Medical Ltd. (OTCQB:TOMDF) announced it has entered into a letter of intent (LOI) with Acumen Diagnostics of Singapore for its CLIA/CAP-certified clinical testing lab Provista Diagnostics to license the laboratory-developed test (LDT) rights to commercialize the sepsis PCR-based diagnostic test AcuSept in the US.
Todos Medical Ltd CEO Gerald Commissiong has shared the company's aim to open a prospective study to confirm the usefulness of its dietary supplement Tollovid in cases of Long COVID. The CEO discussed the plan in a statement expressing the company's support for International Long COVID Awareness Day on March 15.
No recent filings indexed.